41 results about "Heparan sulphate proteoglycan" patented technology

The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.

The invention relates to a preparation process for cornstalk pentosane sulfate and belongs to the technical field of natural product structural transformation and application. According to the preparation process for the cornstalk pentosane sulfate, the target product pentosane sulfate is synthesized via a two-step reaction; the molecular structure of the pentosane sulfate is similar to that of heparin and the pentosane sulfate can be used as a raw material for synthesizing an anticoagulant active drug. The preparation process for the cornstalk pentosane sulfate, provided by the invention, has the advantages of simple and convenient operation, small pollution, high sulfation degree, wide raw material source, good market application prospect and so on.

The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and / or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and / or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.

The invention relates to a highly biologically active extracellular matrix material and its preparation method and application. The raw material is prepared by combined use of ultra-high pressure and perfusion inside and outside the cavity. The preparation method mainly includes: acquisition and preparation of raw materials, pre-treatment; mechanical separation of extracellular matrix; ultra-high pressure crushing and decellularization; washing out cell contents and removing antigens; final sterilization and preservation. Compared with the extracellular matrix obtained by decellularization by mechanical oscillation method, chemical reagent or biological reagent method, the present invention significantly improves the concentration of cohesin, growth factor, proteoglycan, glycoprotein, glycosaminoglycan, etc. The retention of biologically active components; at the same time, the mechanical strength is well preserved, the decellularization is thorough, and the biological load such as viruses is completely removed; the industrial production is convenient.

The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

The allosteric effectors, sulfate and phosphate, can be used with mannanohydrolase enzymes to better control the break of gelled fracturing fluids in wellbore operations. The fracturing fluid contains a hydratable polymer of guar, a guar derivative, a cellulose derivative, a water soluble biopolymer or a combination thereof and a crosslinking agent. The mannanohydrolase enzyme catalyzes the hydrolysis of β-(1,4) mannosidic linkages to break the polymeric backbone.

The present invention provides novel compounds and pharmaceutical compositions containing such compounds, wherein the compounds have affinity for proteoglycans. The compounds comprise an amino acid based core unit linked to positively charged moieties. The compounds further comprise at least one imaging moiety detectable in in vivo imaging making the compounds useful as diagnostic contrast agents for imaging of proteoglycans, such as heparan sulphate proteoglycans.

The invention relates to a landfill leachate sludge dewatering composite biological enzyme conditioner as well as a preparation method and a use method thereof. The conditioner comprises the following components in percentage by mass: 10-15% of cellulase; 5-8% of xylanase; 3-5% of laccase; 8-10% of pectinase; 12-18% of protease; 5-8% of chitosanase; 5-10% of lipase; 8-12% of fatty acid sorbitan; 10-15% of hexadecyl trimethyl bromide; 2-5% of sodium chloride; 1-3% of potassium sorbate; and 3-20% of deionized water. The components can be used for dewatering landfill leachate sludge after being mixed, extracellular polymeric substances in the sludge are extracted and damaged by the aid of the enzyme and the surfactant, so that water bound to the sludge is reduced, meanwhile, colloids and fine fibers in the sludge are modified and degraded by the conditioner, the filtering speed of water in the sludge is increased. The treated sludge is flocculated through a flocculating agent PAM, and finally, the dryness of the leachate sludge can be greatly improved through filter pressing and dewatering treatment, the dryness of the sludge after filter pressing can reach 55-65%, and the sludge can be directly incinerated together with garbage.

The present disclosure relates to a device and an in vitro method for quantitatively determining the presence or absence of one or more acute phase proteins in a biological sample from an individual. Said method comprises contacting a biological sample from the individual with a device to determine relative levels of acute phase proteins produced during bacterial infection and correlating the determined levels to infection. The device used is based on inverted methachromacy and the detection level of said method and device depends on the ratio of proteoaminoglycan to Toluidine blue in the solution. The device and method can detect a bacterial infection or monitor an antibiotic therapy.

The invention relates to a drug balloon, comprising a balloon body and a catheter connected with the balloon body, the outer surface of the balloon body is provided with a drug, and the outer side of the drug is wrapped with a riboglycan film. The drug balloon provided by the present invention can effectively protect the drug and prevent a large amount of loss of the drug by disposing the riboglycan film on the outside of the drug. The sore has a hemostatic effect.

The invention discloses an application of fucosan sulfate in promoting autophagy of foam cells to decompose ox-LDL, belonging to the technical field of pharmaceutical preparations. The fucosan sulfatecan promote cell autophagy to decompose excessive ox-LDL in the foam cells, so a new direction is provided for the foam cells to recover to normal macrophages, and a new idea is provided for application of the fucosan sulfate.

The invention provides sea mushroom fucoidan sulfate and its application in the preparation of medicines and functional products for preventing and treating leukopenia. The present invention proves through cell experiments that the fucoidan sulfate can significantly promote the formation of granulocyte-macrophage hematopoietic progenitor cell colonies, and at the same time can promote the proliferation of bone marrow stromal cells. In vivo experiments further show that the fucoidan sulfate can significantly inhibit the decrease of leukocytes, neutropenia and thrombocytopenia in mice caused by cyclophosphamide, and increase the number of bone marrow nucleated cells in mice. The fucoidan sulfate provided in the present invention has the effect of antagonizing the myelosuppression caused by chemotherapeutic drugs, and can be used as a functional component for the development of drugs and functional products for preventing and treating leukopenia.

The present invention provides a kind of proteoglycan FMP-6-S4 containing galacturonan obtained from mulberry fruit (Fructus Mori), its preparation method, and described proteoglycan FMP-6-S4 in the preparation prevention and / or treatment of neurodegenerative diseases, inhibition of Aβ 42 Generation or aggregation or use in drugs or health products for Alzheimer's disease. The proteoglycan FMP‑6‑S4 comprises 78% to 82% by weight polysaccharide and 18% to 22% by weight protein; the polysaccharide is composed of galacturonic acid, galacturonic acid Lactose, arabinose, rhamnose and glucose. The proteoglycan FMP-6-S4 has a potential therapeutic effect on Alzheimer's disease, and is expected to be developed as a drug for treating Alzheimer's disease.

The present invention discloses acid and conjugated enzyme process for preparing fucan in lower molecular weight. Coarse fucan is enzymolyzed with commercial pectinase under controlled enzymolysis time, temperature and pH value and intercepted with ultrafiltering film of molecular weight 1000-5000 Da to obtain low molecular weight fucan. The present invention has simple operation, mild condition, high yield, low sulfate radical dropping rate, low cost and other advantages, and is easy use in industrial production. The present invention has simultaneous fucan extraction and lower molecular weight fucan preparation, and has simplified technological process, high production efficiency and over 30 % lowered production cost. In addition, the process uses no harmful chemical reagent, and the product is safe, non-toxic and especially suitable for producing functional food and medicine.

A new biomaterial is disclosed. The biomaterial is prepared by mixing glycosaminoglycan with a phosphoric acid, phosphate ester, or salt or derivative thereof under the action of a catalyst in a liquid reaction medium at a pH of 2.1 to 4.9. The obtained material is capable of enhancing the immunological resistance in human and in animals, treating diseases in human and in animals caused by viruses or bacteria, strengthening the anti-stress ability of animals, improving the appetite of animals, promoting the growth of animals, inhibiting the growth of tumor, lowering blood fat level, as well as preventing and treating viral diseases in plants.

The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing / treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.